Who to call at Lynk Pharmaceuticals, and when
Fundz watches for the moments Lynk Pharmaceuticals starts buying, and tells you who to reach.
- An alert the day Lynk Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Lynk Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Lynk Pharmaceuticals. With Fundz connected, it knows.
Lynk Pharmaceuticals and Simcere Expand Partnership for Zemprocitinib Commercialization in Greater China.
Contract Type
partnership
Description
Lynk Pharmaceuticals has expanded its partnership with Simcere Pharmaceutical Group for the commercialization of zemprocitinib, targeting atopic dermatitis in Greater China. This agreement grants Simcere exclusive rights across mainland China, Hong Kong, Macau, and Taiwan, building on their previous collaboration. The expanded partnership aims to enhance market development and patient access to the drug.
Quick answer
Lynk Pharmaceuticals and Simcere Expand Partnership for Zemprocitinib Commercialization in Greater China. (November 3, 2026). Lynk Pharmaceuticals is based in Hangzhou, Zhejiang, China.
- What agreement did Lynk Pharmaceuticals announce on November 3, 2026?
- Lynk Pharmaceuticals has expanded its partnership with Simcere Pharmaceutical Group for the commercialization of zemprocitinib, targeting atopic dermatitis in Greater China. This agreement grants Simcere exclusive rights across mainland China, Hong Kong, Macau, and Taiwan, building on their previous collaboration.
- What does Lynk Pharmaceuticals do?
- Lynk Pharmaceuticals, a clinical stage company, was founded in 2018 by senior drug R&D experts and executives from Pfizer, Merck and Johnson & Johnson.
- Where is Lynk Pharmaceuticals based?
- Lynk Pharmaceuticals is based in Hangzhou, Zhejiang, China.
- Which similar companies announced agreements around the same time?
- AbbVie Inc. (November 3, 2026), Teva Pharmaceutical Industries Ltd (November 3, 2026), Fresenius SE & KGaA (November 3, 2026) and Aarvik Therapeutics (November 3, 2026) also announced agreements within 45 days of Lynk Pharmaceuticals.
Source: Fundz verified event record.
Other recent agreements in Science And Engineering and Biotechnology
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- AbbVie partners with McLaren Racing in a multiyear collaboration to promote liver health awareness through Formula 1. (November 3, 2026)
- Teva and Samsung Bioepis Sign Agreement for U.S. Rights to Biosimilars Infliximab and Etanercept. (November 3, 2026)
- Fresenius Enters Exclusive 10-Year Partnership with WuXi Biologics for Biosimilar Development. (November 3, 2026)
- Aarvik Therapeutics Enters Partnership with Laurus Labs for MUTTA™ ADC Development in India. (November 3, 2026)
- Wildcat Defense partners with Taqtile to deploy digital tools in shipyards. (November 4, 2026)
- AbbVie secures exclusive licensing rights to Nxera’s EP4 program for inflammatory bowel disease with a $100 million payment. (November 4, 2026)
Agreement Insights
What this usually meansLynk Pharmaceuticals signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.